Dr. Civin’s Lab
Dr. Civin is a renowned leader and innovator in laboratory research on blood and immune system development, leukemia, stem cell transplantation, and gene therapy. Dr. Civin joined the University of Maryland School of Medicine in January 2009 as the founding Director of the Center for Stem Cell Biology and Regenerative Medicine, and Associate Dean for Research in the School of Medicine.
Dr. Civin was recognized as the National Inventor of the Year in 1999, and received the prestigious Karl Landsteiner Memorial Award and Lectureship* in 2009, both for his pioneering breakthrough discovery of the CD34 antibody, which has had a major impact on the field of blood research. Dr. Civin also co-discovered human FLT3 receptor, a myeloid growth factor receptor that is frequently mutated in leukemias. With the discovery of the CD34+ and the FLT3 receptor, Dr. Civin accomplished the rare feat of making two field-opening laboratory discoveries that he and his colleagues then brought to their own patients as novel therapeutics. In this process, Dr. Civin has mentored (trained and inspired) a large number of talented trainees to pursue academic careers in translational research.
Dr. Civin is currently a principal or collaborating investigator on 13 peer reviewed research projects totaling nearly $5M (and over $20M, including awards that he still participates in, but are centered at Johns Hopkins). His lab is funded by the National Institutes of Health, the State of Maryland Stem Cell Research Fund, the Leukemia & Lymphoma Society and other private foundations. His collaborative research includes both basic science and translational/clinical research projects with entities including the Johns Hopkins University, the Howard Hughes Medical Institute, the University of Maryland Center for Vascular & Inflammatory Diseases and the University of Maryland Greenebaum Cancer Center. He is an inventor of nine biomedical patents that have emanated from his research, which now focuses mainly on normal and malignant stem cells.
Dr. Civin has lectured around the world, published more than 250 articles and book chapters, received many awards, and served in leadership positions of multiple distinguished committees and editorial boards, such as Editor-in-Chief of Stem Cells from 2000-2007.
* The Landsteiner Award was initiated by the American Association of Blood Banks in 1955 to honor Karl Landsteiner MD, whose Nobel Prize-winning discoveries of the ABO and Rh blood group antigens laid the foundation for modern blood transfusion therapy. It recognizes a scientist whose original research resulted in an important contribution to the body of scientific knowledge and who has an international reputation in blood transfusion medicine or a related field.